7 Std. · Late last week, researchers funded by the National Institutes of Health's Vaccine Research Center announced they neutralized the Ebola virus in primates up to five days after infection using antibodies taken from a human Ebola survivor. DARPA is now building on that research to combine those antibodies with other protective antibodies identified during the recent Ebola outbreak to develop a prophylactic treatment for people in danger of becoming infected during future outbreaks. To help meet the volume demand for such a treatment, DARPA is funding Inovio to develop DNA-based immunotherapies -- encoding the genes for the antibodies -- to enable a patient's own muscle cells to make the antibodies that defend against Ebola. For more information on Inovio's work visit: http://www.inovio.com/produc…/infectious-disease-vaccines/…/
Thread abonnieren
